 |
|
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Ferris and colleagues suggest that we incorrectly assumed that he and his coauthors, Dr Kirby and Dr Thal, were "uninvolved ‘guest’ authors " and is critical that we did not contact him prior to publication of the article by Ross et al.1 However, had we contacted Ferris for such clarification, the available evidence would have confirmed our concerns. Although Ferris, Kirby, and Thal apparently were involved with various aspects of the Merck Rofecoxib 078 study, including reportedly assisting with study design, enrolling patients, and serving on the end point adjudication committee, it appears that these individuals had limited involvement as authors responsible for the manuscript.
As Ferris et al indicate in their letter, the manuscript was drafted in August 2003 by Merck employees, and only after that were Ferris, Kirby, and Thal "approached about being coauthors on the paper." In a September 12, 2003, e-mail correspondence sent . . . [Full Text of this Article]
Catherine D. DeAngelis, MD, MPH
Editor in Chief, JAMA
Phil B. Fontanarosa, MD, MBA
Executive Deputy Editor, JAMA
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies--Reply
and
JAMA. ;294():2576-2577.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():900-900.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():900-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():901-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():901-901.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
, , and
JAMA. ;300():901-902.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():902-902.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():902-903.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
JAMA. ;300():903-903.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():903-904.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():904-904.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():904-904.
FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
, , and
JAMA. ;300():904-905.
FULL TEXT
RELATED ARTICLES
Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals
, , , , , , and
JAMA. ;280():222-224.
FULL TEXT
Prevalence of Honorary and Ghost Authorship in Cochrane Reviews
, , , , , , , , and
JAMA. ;287():2769-2771.
FULL TEXT
Reporting Conflicts of Interest, Financial Aspects of Research, and Role of Sponsors in Funded Studies
, , and
JAMA. ;294():110-111.
FULL TEXT
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
, , , and
JAMA. ;299():1800-1812.
FULL TEXT
Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
and
JAMA. ;299():1813-1817.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals
Hirsch
Mayo Clin Proc. 2009;84:811-821.
FULL TEXT
|
